The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Using MRD Status to Deescalate Multiple Myeloma Therapy

2.

A new theranostic drug targets different cancer types.

3.

Patients face high out-of-pocket costs after incident cancer diagnosis

4.

Is Exercise an Effective Treatment for Prostate Cancer?

5.

Brain cancer: a Q&A session.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot